Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease

NCT06392425 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT06392425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06392425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease
Lead sponsor
Assiut University
Phase
Observational
Overall status
Not yet recruiting
Start date
April 26, 2024
Completion date
October 31, 2027
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases